
    
      Part 1: to evaluate the safety and tolerability of ODM-209, to define the maximum tolerated
      dose (MTD) and dose limiting toxicities (DLTs) of ODM-209, if feasible, to define the
      recommended dose of ODM-209 and replacement therapy for Part 2 of the study.

      Part 2: to further evaluate the safety and tolerability of ODM-209, to evaluate the
      preliminary anticancer activity of ODM-209.
    
  